Literature DB >> 33501547

[11C]meta-hydroxyephedrine PET evaluation in experimental pulmonary arterial hypertension: Effects of carvedilol of right ventricular sympathetic function.

Jason G E Zelt1,2,3, Sarah Schock4, Robert A deKemp5, Duncan J Stewart6,7,8, William A Staines4, Ali Ahmadi5, Rob Beanlands5,6,7, Lisa M Mielniczuk5,6,7.   

Abstract

BACKGROUND: Little is known about the sequelae of chronic sympathetic nervous system (SNS) activation in patients with pulmonary arterial hypertension (PAH) and right heart failure (RHF). We aimed to, (1) validate the use of [11C]-meta-hydroxyephedrine (HED) for assessing right ventricular (RV) SNS integrity, and (2) determine the effects of β-receptor blockade on ventricular function and myocardial SNS activity in a PAH rat model.
METHODS: PAH was induced in male Sprague-Dawley rats (N = 36) using the Sugen+chronic hypoxia model. At week 5 post-injection, PAH rats were randomized to carvedilol (15 mg·kg-1·day-1 oral; N = 16) or vehicle (N = 16) for 4 weeks. Myocardial SNS function was assessed with HED positron emission tomography(PET).
RESULTS: With increasing PAH disease severity, immunohistochemistry confirmed selective sympathetic denervation within the RV and sparing of parasympathetic nerves. These findings were confirmed on PET with a significant negative relationship between HED volume of distribution(DV) and right ventricular systolic pressure (RVSP) in the RV (r = -0.90, p = 0.0003). Carvedilol did not reduce hemodynamic severity compared to vehicle. RV ejection fraction (EF) was lower in both PAH groups compared to control (p < 0.05), and was not further reduced by carvedilol. Carvedilol improved SNS function in the LV with significant increases in the HED DV, and decreased tracer washout in the LV (p < 0.05) but not RV.
CONCLUSIONS: PAH disease severity correlated with a reduction in HED DV in the RV. This was associated with selective sympathetic denervation. Late carvedilol treatment did not lead to recovery of RV function. These results support the role of HED imaging in assessing SNS innervation in a failing right ventricle.

Entities:  

Keywords:  Beta adrenergic blockade; Positron emissions tomography; Pulmonary arterial hypertension; Right heart failure; Sympathetic nervous system

Mesh:

Substances:

Year:  2021        PMID: 33501547     DOI: 10.1007/s12350-020-02494-6

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  28 in total

1.  Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.

Authors:  Harm J Bogaard; Ramesh Natarajan; Shiro Mizuno; Antonio Abbate; Philip J Chang; Vinh Q Chau; Nicholas N Hoke; Donatas Kraskauskas; Michael Kasper; Fadi N Salloum; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

2.  Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study.

Authors:  Jasmijn S J A van Campen; Karin de Boer; Mariëlle C van de Veerdonk; Cathelijne E E van der Bruggen; Cor P Allaart; Pieter G Raijmakers; Martijn W Heymans; J Tim Marcus; Hendrik J Harms; M Louis Handoko; Frances S de Man; Anton Vonk Noordegraaf; Harm-Jan Bogaard
Journal:  Eur Respir J       Date:  2016-07-07       Impact factor: 16.671

3.  Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension.

Authors:  Steeve Provencher; Philippe Herve; Xavier Jais; Didier Lebrec; Marc Humbert; Gerald Simonneau; Olivier Sitbon
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

4.  Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension.

Authors:  Agnieszka Ciarka; Vi Doan; Sonia Velez-Roa; Robert Naeije; Philippe van de Borne
Journal:  Am J Respir Crit Care Med       Date:  2010-03-01       Impact factor: 21.405

5.  The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale.

Authors:  Lewis J Rubin
Journal:  Eur Respir J       Date:  2016-09       Impact factor: 16.671

6.  Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Authors:  Samar Farha; Didem Saygin; Margaret M Park; Hoi I Cheong; Kewal Asosingh; Suzy Aa Comhair; Olivia R Stephens; Emir C Roach; Jacqueline Sharp; Kristin B Highland; Frank P DiFilippo; Donald R Neumann; W H Wilson Tang; Serpil C Erzurum
Journal:  JCI Insight       Date:  2017-08-17

7.  Effects of myricetin on the bioavailability of carvedilol in rats.

Authors:  W Lee; E R Woo; J S Choi
Journal:  Pharm Biol       Date:  2011-12-01       Impact factor: 3.503

8.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

Review 9.  The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.

Authors:  Filippos Triposkiadis; George Karayannis; Grigorios Giamouzis; John Skoularigis; George Louridas; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2009-11-03       Impact factor: 24.094

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.